Drawing for SIMPLY CSL

USPTO serial 87465341

SIMPLY CSL

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
VAGHANI, MAYUR C
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with SIMPLY CSL?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Scott D. Woldow

Scott D. Woldow Smith, Gambrell & Russell, LLP1055 Thomas Jefferson St. NW, Suite 400Washington, DC 20007UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
009Downloadable audio files, multimedia files, text files, e-mails, written documents, audio material video material and games featuring information in the form of downloadable educational/training communications in the fields of in the field of illnesses, diseases and health-related and medical therapies, human resource development for the promotion of employee retention, career growth, and increased productivity for employees and employersACTIVE—
016Printed matter and publications, namely, printed instructional material and magazines featuring pharmaceutical products, vaccines, blood, blood products, bleeding disorders, blood fractionations, rhesus prophylaxis and human autoimmune disorders; printed instructional and teaching materials in the field of pharmaceutical products, vaccines, blood, blood products, bleeding disorders, blood fractionations, rhesus prophylaxis and human autoimmune disorders; brochures, pamphlets and informational flyers in the field of pharmaceutical products, vaccines, blood, blood products, bleeding disorders, blood fractionations, rhesus prophylaxis and human autoimmune disorders; posters; stationeryACTIVE—
036Processing, administration and managing employee benefit plans and employee welfare benefit plans concerning insurance and finance; Providing information in the field of employee financial benefit plansACTIVE—
041Providing continuing medical education courses; arranging and conducting of educational conferences in the field of health care and medical therapies; development and dissemination of printed educational materials of others in the field of health care and medical therapies; publication of educational and training guides in the field of health care and medical therapies; providing educational courses in the field of diet and health care; Educational services, namely, arranging and conducting classes, seminars, conferences, workshops, in the field of health-related and medical therapies and related business education programs and distribution of training material in connection therewith; Educational services, namely, providing a learning and innovation center featuring customized leadership, motivational, educational, and brainstorming training in the field of health care and medical therapies; Business education and training services, namely, developing customized and customized in-company leadership and executive development programs, providing executive coaching services, providing business education programs to employees and executives, and providing public and in-company keynote presentations to business leaders in the field of health care and medical therapies; Educational and entertainment services, namely, providing motivational and educational speakers in the field of health care and medical therapies, and speakers in the field of self- and personal improvementACTIVE—
042Providing scientific information in the field of health care and medical therapies; scientific information services in the field of health care and medical therapies provided via the Internet; providing research information on donation of human blood for medical research; providing medical and scientific research information about the results of clinical trials for pharmaceutical productsACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Jul 11, 2022MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Jul 11, 2022ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Nov 16, 2021EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Nov 15, 2021EX5GSOU EXTENSION 5 GRANTED—
Nov 8, 2021AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Nov 4, 2021EXT5SOU EXTENSION 5 FILED—
Nov 4, 2021EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
May 6, 2021EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
May 4, 2021EX4GSOU EXTENSION 4 GRANTED—
May 4, 2021EXT4SOU EXTENSION 4 FILED—
May 4, 2021EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Nov 6, 2020EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Nov 4, 2020EX3GSOU EXTENSION 3 GRANTED—
Nov 4, 2020EXT3SOU EXTENSION 3 FILED—
Nov 4, 2020EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jun 4, 2020EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jun 2, 2020EX2GSOU EXTENSION 2 GRANTED—
Jun 2, 2020EXT2SOU EXTENSION 2 FILED—
Jun 2, 2020EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Nov 13, 2019EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Nov 11, 2019EX1GSOU EXTENSION 1 GRANTED—
Nov 11, 2019EXT1SOU EXTENSION 1 FILED—
Nov 11, 2019EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jun 4, 2019NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Apr 26, 2019ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Apr 26, 2019REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Apr 9, 2019NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Apr 9, 2019PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Mar 20, 2019NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Mar 6, 2019CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Feb 15, 2019TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Feb 15, 2019CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Feb 15, 2019CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Feb 15, 2019ALIEASSIGNED TO LIE—
Feb 11, 2019ERSITEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED—
Dec 17, 2018ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Dec 17, 2018REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Aug 23, 2018GNS2NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED—
Aug 23, 2018GNSIINQUIRY TO SUSPENSION E-MAILED—
Aug 23, 2018CNSISUSPENSION INQUIRY WRITTEN—
Feb 13, 2018GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Feb 13, 2018GNSLLETTER OF SUSPENSION E-MAILED—
Feb 13, 2018CNSLSUSPENSION LETTER WRITTEN—
Jan 24, 2018TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jan 24, 2018CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jan 22, 2018ALIEASSIGNED TO LIE—
Jan 5, 2018TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jul 19, 2017GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 19, 2017GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 19, 2017CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 14, 2017DOCKASSIGNED TO EXAMINER—
Jun 2, 2017NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
May 30, 2017NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance